Cybin's Psilocybin Analog CYB003 Gets FDA Clearance For Trial To Potentially Treat Major Depressive Disorder

Psychedelic biopharma company Cybin Inc. CYBN has received FDA  Investigational New Drug Application (IND) approval for a Phase 1/2a clinical trial evaluating its proprietary CYB003 for treating major depressive disorder (MDD).

The company had previously been granted approval for the study from the Institutional Review Board, a group that works under FDA regulations. The IND acceptance, though, constitutes a milestone as it will be the industry’s first novel psilocybin analog to enter clinical development

“Multiple academic studies have shown that psychedelic-based treatments, like psilocybin, may have the potential to revolutionize mental healthcare, but few companies have addressed the well-known limitations and side effects of oral psilocybin," said CEO Doug Drysdale. "We believe CYB003 has the potential to offer people in need with a more tolerable and potentially more effective treatment option.”

CYB003 is a deuterated analog of psilocybin, designed to potentially address the challenges and limitations of oral psilocybin. It is included in a family of molecules called indolamines along with more common neurotransmitters such as serotonin. 

Preclinical data shows that CYB003 achieved less variability in plasma levels, faster onset of action and shorter duration of effect compared to oral psilocybin.

For the current study, the company is working with drug development Clinilabs. The CYB003 Phase 1/2a trial is a randomized, double-blind, placebo-controlled study evaluating people with moderate to severe MDD. Participants will receive two administrations (placebo/active and active/active) and a response/remission will be assessed at Week 3 (after the first dose) and at Week 6 (after the second dose). 

The trial is set to evaluate rapid onset antidepressant effects as well as that of up to two doses of 12mg, providing important pharmacokinetics and safety data to determine a clinical path forward.

An optional open-label follow-up study will assess the durability of the treatment effect for up to 12 weeks.

Posted In: Doug DrysdaleFDA ApprovalBiotechCannabisNewsPsychedelicsLegalMarketsGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.